Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome

Next Previous
X
Search
Trial Profile

A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glenzocimab (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms GARDEN
  • Sponsors Acticor Biotech

    • Most Recent Events

    • 15 Nov 2021 Preliminary clinical data (as of May 31, 2021; n=50) assessing safety and efficacy of glenzocimab in patients with COVID-19 related ARDS presented at the American Heart Association Scientific Sessions 2021
    • 10 Sep 2021 Status changed from active, no longer recruiting to completed.
    • 04 Sep 2021 This trial has been completed in France, as per European Clinical Trials Database record. (2021-08-06)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top